Market Place
Sourcing Support
Compugen To Join 25Th Annual Needham Healthcare Conference
09 Apr 2026 //
PR NEWSWIRE
Compugen To Participate In Upcoming Investor Conferences
19 Feb 2026 //
PR NEWSWIRE
Compugen To Unveil Q4 And Full Year 2025 Results On March 2, 2026
17 Feb 2026 //
PR NEWSWIRE
Compugen Appoints Michele Holcomb, Ph.D., To Board of Director
12 Feb 2026 //
PR NEWSWIRE
Compugen Monetizes AstraZeneca Rilvegostomig Royalties Up to $90M
17 Dec 2025 //
PR NEWSWIRE
Compugen To Participate In Stifel 2025 Healthcare Conference
04 Nov 2025 //
PR NEWSWIRE
Compugen to Share Research at Single Cell Genomics 2025 Event
08 Sep 2025 //
PR NEWSWIRE
Compugen to Present at HC Wainwright Global Investment Conference
28 Aug 2025 //
PR NEWSWIRE
Compugen Reports Second Quarter 2025 Results
07 Aug 2025 //
PR NEWSWIRE
Compugen to Present AI/ML Research at Scientific Conferences
12 Jun 2025 //
PR NEWSWIRE
Compugen Reports First Quarter 2025 Results
19 May 2025 //
PR NEWSWIRE
Compugen Announces Leadership Transitions in September 2025
13 May 2025 //
PR NEWSWIRE
Compugen to Release Q1 2025 Results on May 19, 2025
05 May 2025 //
PR NEWSWIRE
Compugen to Join Virtual Investor Conferences in April 2025
26 Mar 2025 //
PR NEWSWIRE
Compugen To Join Fireside Chat At 2025 Leerink Healthcare Conf
03 Mar 2025 //
PR NEWSWIRE
Compugen Reports Q3 2024 Results
12 Nov 2024 //
PR NEWSWIRE
Compugen to Participate in Stifel 2024 Healthcare Conference
11 Nov 2024 //
PR NEWSWIRE
Compugen To Release Q3 2024 Financial Results On Nov 12
29 Oct 2024 //
PR NEWSWIRE
Compugen to Present New Clinical Data at SITC 2024
07 Oct 2024 //
PR NEWSWIRE
Compugen To Present At H.C. Wainwright Investment Conference
29 Aug 2024 //
PR NEWSWIRE
Compugen Reports Second Quarter 2024 Results
06 Aug 2024 //
PR NEWSWIRE
Compugen To Present At Antibody Industrial Symposium
17 Jun 2024 //
PR NEWSWIRE
Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering
30 May 2024 //
ENDPTS
Compugen Reports First Quarter 2024 Results
20 May 2024 //
PR NEWSWIRE
Compugen Paper On PVRIG Biology, Therapeutic Potential
16 May 2024 //
PR NEWSWIRE
Compugen Appoints David Silberman as Chief Financial Officer
15 May 2024 //
PR NEWSWIRE
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
06 May 2024 //
PR NEWSWIRE
Compugen to Participate in Two Upcoming Investor Conferences
03 Apr 2024 //
PR NEWSWIRE
Compugen Selected for Oral Presentations at Symposium on Cancer Immunotherapy
11 Mar 2024 //
PR NEWSWIRE
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline
06 Mar 2024 //
PR NEWSWIRE
Compugen Reports Fourth Quarter and Full Year 2023 Results
05 Mar 2024 //
PR NEWSWIRE
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
26 Feb 2024 //
PR NEWSWIRE
Compugen to Release Fourth Quarter and Full Year 2023 Results
20 Feb 2024 //
PR NEWSWIRE
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
15 Feb 2024 //
PR NEWSWIRE
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
08 Jan 2024 //
PR NEWSWIRE
Gilead nabs rights to Compugen’s IL-18 immunotherapy programme
20 Dec 2023 //
PRESS RELEASE
Compugen Reports Third Quarter 2023 Results
07 Nov 2023 //
PR NEWSWIRE
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
03 Nov 2023 //
PR NEWSWIRE
Compugen to Present New Data at SITC 2023
31 Oct 2023 //
PR NEWSWIRE
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
24 Oct 2023 //
PR NEWSWIRE
Compugen Expands Intellectual Property with New Japanese Patent
02 Oct 2023 //
PR NEWSWIRE
Compugen Reports Second Quarter 2023 Results
07 Aug 2023 //
PR NEWSWIRE
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
24 Jul 2023 //
PR NEWSWIRE
Compugen Wins on PVRIG EU Patent Opposition Pursued by GSK and a Third Party
17 Jul 2023 //
PR NEWSWIRE
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
13 Jun 2023 //
PR NEWSWIRE
Compugen Reports First Quarter 2023 Results
15 May 2023 //
PR NEWSWIRE
Compugen to Present at the JMP Securities Life Sciences Conference
09 May 2023 //
PR NEWSWIRE
Compugen to Present New Clinical Data Showing Anti-Tumor Activity of COM701
27 Apr 2023 //
PR NEWSWIRE
Compugen to Present Data on its Lead Pre-Clinical Asset COM503
26 Apr 2023 //
PR NEWSWIRE
Compugen to Present Study of Novel Target PVRIG at AACR 2023
15 Mar 2023 //
PR NEWSWIRE
Compugen to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
08 Mar 2023 //
PR NEWSWIRE
Compugen Reports Fourth Quarter and Full Year 2022 Results
27 Feb 2023 //
PR NEWSWIRE
Compugen to Release Fourth Quarter and Full Year 2022 Results on February 27
13 Feb 2023 //
PR NEWSWIRE
Compugen to Present at the SVB Securities Global Biopharma Conference
09 Feb 2023 //
PR NEWSWIRE
Compugen`s COM701 in Combination Demonstrates Durable Anti-Tumor Activity
06 Dec 2022 //
PRNEWSWIRE
Compugen touts ovarian cancer data in combo with Opdivo
06 Dec 2022 //
ENDPTS
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
29 Nov 2022 //
PRESS RELEASE
Compugen to Receive Milestone Payment Triggered by AZ`s PD-1/TIGIT Bispecific
16 Nov 2022 //
PRESS RELEASE
Compugen Reports Third Quarter 2022 Results
14 Nov 2022 //
PRNEWSWIRE
Compugen to Participate in the Stifel Healthcare Conference
08 Nov 2022 //
PRESS RELEASE
